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Abstract
Summary Altogether 95 children with primary bone fragility
were screened for variants in PLS3, the gene underlying X-
linked osteoporosis. Two children with multiple peripheral
and spinal fractures and low BMD had novel disease-
causing PLS3 variants. Children with milder phenotypes had
no pathogenic variants. PLS3 screening is indicated in
childhood-onset primary osteoporosis.
Introduction The study aimed to determine the role of patho-
genic PLS3 variants in children’s bone fragility and to eluci-
date the associated phenotypic features.
Methods Two cohorts of children with bone fragility were
screened for variants in PLS3, the gene underlying X-linked
osteoporosis. Cohort I comprised 31 patients with childhood-
onset primary osteoporosis of unknown etiology. Cohort II
comprised 64 children who had sustained multiple fractures
but were otherwise healthy. Clinical and radiological data
were reviewed. Peripheral blood DNAwas Sanger sequenced
for coding exons and flanking intronic regions of PLS3.
Results In two patients of cohort I, where other common ge-
netic causes had been excluded, we identified two novel
disease-causing PLS3 variants. Patient 1 was a male with
bilateral femoral fractures at 10 years, low BMD (Z-score
−4.1; 18 years), and multiple vertebral compression fractures.
He had a novel nonsense variant in PLS3. Patient 2 was a girl
with multiple long bone and vertebral fractures and low BMD
(Z-score −6.6 at 6 years). She had a de novo missense variant
in PLS3; whole exome sequencing and array-CGH identified
no other genetic causes. Iliac crest bone biopsies confirmed
low-turnover osteoporosis in both patients. In cohort II, no
pathogenic PLS3 variants were identified in any of the
subjects.
Conclusions Two novel disease-causing variants in PLS3
were identified in a boy and a girl with multiple peripheral
and spinal fractures and very low BMD while no pathogenic
variants were identified in children with less severe skeletal
fragility. PLS3 screening is warranted in male and female pa-
tients with childhood-onset primary osteoporosis.
Keywords Children . Early-onset osteoporosis . Fractures .
Osteogenesis imperfecta . Plastin 3 . X-Linked osteoporosis
Introduction
Childhood-onset primary osteoporosis is a rare but clinically
important condition characterized by reduced bone strength
and an elevated risk of fractures [1]. Current definition
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requires a clinically significant fracture history and BMD Z-
score at or below −2.0. A clinically significant fracture history
is defined as (1) two or more long bone fractures ≤10 years
and (2) three or more long bone fractures ≤19 years [2]. When
vertebral compression fractures are present, they alone can be
grounds for the diagnosis even when BMD is normal [2]. The
diagnosis further requires that other nutritional or medical
causes for the child’s bone fragility have been excluded.
With such a broad definition, it is easy to understand that
childhood-onset primary osteoporosis includes a spectrum of
skeletal diseases with different molecular causes. Most affect-
ed children are classified as having osteogenesis imperfecta
(OI), in which the great majority of cases are due to pathogen-
ic variants in either COL1A1 or COL1A2, the two genes
encoding type I collagen [3, 4]. However, during the last
10 years, studies have shown that pathogenic variants in 20
different genes can cause childhood-onset primary osteoporo-
sis [5–11].
PLS3, located on the X chromosome, is one of the most
recently described genes underlying childhood-onset primary os-
teoporosis. PLS3 osteoporosis was first described in five families
with apparent X-linked osteoporosis in 2013, and the gene was
subsequently shown to be of importance in bone metabolism
[12]. PLS3 codes for the protein Plastin3, which is widely
expressed in solid tissues and thought to be involved in cytoskel-
eton remodeling. Plastin3 contains two actin-binding sites and
two calcium-binding sites, and in in vitro experiments, it can
form bundles of actin by crosslinking single filaments to each
other [13, 14]. In bone, Plastin3 has been suggested to either be
part of the osteocytes’ mechanosensing apparatus or play a role
in the mineralization process [12, 15]. Plastin3 has also been
reported as a protective modifier in spinal muscular atrophy
(SMA) and to be important in axonogenesis [16, 17]. A PLS3
knockout mouse model shows decreased BMD and knockdown
of PLS3 in Zebrafish results in craniofacial dysplasia in the de-
veloping Zebrafish larvae [12, 18]. However, as of yet, the direct
function of Plastin3, the mechanism of its action, and pathogen-
esis of PLS3 osteoporosis are still undetermined.
Because of PLS3’s location on the X chromosome, males
are in general more severely affected by loss of function var-
iants than females. PLS3 osteoporosis is foremost character-
ized by vertebral compression fractures, frequent peripheral
fractures, and a low BMD [12, 19]. Other traits common in
classical OI, such as blue sclerae, joint hyperlaxity, and short
stature, are usually not present. However, only eight families
with childhood-onset primary osteoporosis due to pathogenic
variants inPLS3 have been described in the literature, and thus
the features of PLS3 osteoporosis have not been fully charac-
terized [12, 15, 19].
In this study, we have attempted (1) to determine the over-
all role of pathogenic variants in PLS3 in children with bone
fragility and (2) to increase the understanding of the clinical
features of PLS3 osteoporosis.
Materials and methods
This study involves two patient cohorts assessed for primary
skeletal fragility at the Children’s Hospital, Helsinki
University Hospital. The institutional Ethics Review Board
at Helsinki University Hospital approved the study protocol,
and all patients and/or their guardians gave a written informed
consent before participation.
Cohort characteristics
Cohort 1 (Bprimary osteoporosis^) consisted of 31 patients
(17 boys and 14 girls), who had been referred to the
Metabolic Bone Clinic, Children’s Hospital, Helsinki during
the years 2003–2013 for investigation for childhood-onset
primary osteoporosis but where the investigation did not re-
veal a molecular cause of their disease. The inclusion criteria
were (1) exclusion of type I collagen-related OI, either clini-
cally or by genetic testing, and (2) exclusion of secondary
osteoporosis with biochemical and individually determined
clinical evaluations. Further, all had been screened and found
negative for pathogenic variants inWNT1 and LRP5 and sev-
eral had undergone more extensive genetic testing before in-
clusion. At the time of referral, all the patients were between
the ages of 4 and 17 years, displayed clinically an osteoporotic
phenotype, and several of them had similarly affected family
members. Most of the patients (25/31) fulfilled the ISCD
criteria [2] for pediatric osteoporosis. Six patients only had a
history of increased non-spinal fractures and a BMD Z-score
>−2.0 but had other additional features (e.g., osteopenic ap-
pearance on skeletal radiographs, fragile bone on orthopedic
surgery) suggesting osteoporosis.
Cohort II (Bfracture prone^) consisted of 64 otherwise
healthy children who had sustained multiple fractures (43
boys and 21 girls), all recruited at the Children’s Hospital,
Helsinki, Finland during a prospective epidemiological study
[20]. Over a 12-month period, all children (n = 1412) aged 4–
15 years who had been treated for an acute and radiographi-
cally confirmed fracture were assessed for fracture history.
The trauma mechanisms and previous medical histories were
available for 1361 (96%) of the children. The inclusion criteria
for cohort II were (1) age 4–15 years, (2) ≥2 low-energy long
bone fractures before age 10 years, (3) ≥3 low-energy long
bone fractures before age 16 years, or (4) ≥1 low-energy ver-
tebral fracture (loss of ≥20% vertebral height). Children with a
diagnosis or suspicion of OI were excluded, as well as chil-
dren with an underlying disease that could explain their bone
fragility. Altogether 71 patients of the >1400 children fulfilled
these criteria; DNA from peripheral blood was available for
64 of them and they comprised cohort II. Data on blood bio-
chemistry, spinal radiographs, and DXA measurements were
collected for all participants.
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As expected, children in cohort I displayed in general low-
er BMD Z-scores at the lumbar spine and a higher prevalence
of vertebral compression fractures (p < 0.001 and p < 0.004,
respectively) than children in cohort II (Fig. 1). Data for BMD
at the lumbar spine and femoral neck and information about
vertebral compression fractures were not available for four,
six, and three children, respectively, in cohort I. In cohort II,
61% (n = 39) of the children had sustained at least three sig-
nificant fractures, and of them 54% (n = 21) had sustained at
least four significant fractures. Twenty percent (n = 13) had
sustained at least three significant fractures before the age of
10 years, and of them 38% (n = 5) had sustained at least four
significant fractures before the age of 10 years.
Genotyping of PLS3
Genomic DNA was extracted with the Puragene DNA
Purification kit (Gentra), Archive Pure DNA Blood Kit
(5Prime), or QIAamp DNA Blood Maxi Kit (Qiagen).
Primers for PCR amplification were constructed using
Primer3Plus and were derived from the canonical ensemble
transcript (ENST00000355899). Sanger sequencing was per-
formed using BigDye® technology on a 3730 ABI sequencer,
and electropherograms were later interpreted using the Staden
package (version 2.0.0b10). Primers are available upon
request.
Whole exome sequencing
Patient 2 in cohort I together with her nuclear family was
subjected to whole exome sequencing. Sequencing was per-
formed using an Illumina HiSeq 2500 at Science for Life
Laboratory, Stockholm, Sweden. The Agilent SureSelect XT
All Exon V4 target enrichment kit was used for whole exome
capture. All analysis computations were performed on re-
s o u r c e s p r o v i d e d b y SN IC t h r o u g h Upp s a l a
Multidisciplinary Center for Advanced Computational
Science (UPPMAX) [21]. For a full description of the data
processing and analysis, see Supplemental appendix and
Supplemental Fig. 1 (Online Resource).
Array comparative genomic hybridization
For patient 2, a customized 2x400K array (Agilent
Technologies) was used, with enriched probes in 2269
genes, including over 300 genes known to underlie skeletal
diseases. In the specifically targeted genes, this high-
resolution array comparative genomic hybridization
(array-CGH) has an average coverage of one probe per
100 base pairs in coding regions and one probe per 500
base pairs in introns and UTRs. The experiments were
performed using standard procedures, and results were an-
alyzed using Agilent Genomic Workbench 7.0.
Bone histomorphometry
Iliac crest bone biopsies were taken as part of normal diagnos-
tic evaluation for both patients in cohort Iwhowere deemed to
have disease-causing variants in PLS3. For bone turnover as-
sessments, the patients were pre-treated with oral tetracycline
for 2 × 2 days with a 10-day treatment-free interval. The bone
biopsies were analyzed by an experienced histomorphometrist
using a semiautomatic image analyzer (Bioquant Osteo;
Bioquant Image Analysis Corp., Nashville, TN, USA). The
recommendations of the American Society for Bone and
Mineral Research regarding abbreviations and nomenclature
were followed [22]. Age-specific reference values and Z-
scores were calculated for all parameters [23, 24].
Statistical analysis
The statistical analyses were performed using R version 3.3.1.
Because of the distribution of the data, the Mann-Whitney U
test was used to compare BMD between the groups. The chi-
square test was used to test categorical data. A p value <0.05
was considered significant.
Results
Genetic findings in cohort I
Sanger sequencing of PLS3 in cohort I identified two patients
(6.5%) with novel variants in PLS3 that were deemed to be
damaging and causative of their phenotypes (described be-
low). In the remaining 29 patients in cohort I, a total of 7
single nucleotide variants (SNVs) and 1 small deletion were
found (Table 1). Three of the SNVs were found in coding
regions, all were synonymous and with an allele frequency
of at least 4% in the general Finnish population (SISu data-
base); the other four variants were intronic, all previously
reported. One of the synonymous variants, rs140121121, has
previously been associated with osteoporosis [12], but this
SNV was not enriched in our cohort compared with the nor-
mal Finnish population (allele frequency 0.067 vs 0.051).
Outside the coding region, we found one 13 bp deletion
(rs201765481) situated 190 bp upstream of exon 6 of PLS3.
Its allele frequency was higher than expected in our cohort
(0.043 vs 0.009 (dbSNP)), but when we sequenced this region
for 96 healthy Finnish control samples, the frequency was
found to be similar (0.059) as in our cohort, suggesting that
the deletion is not pathogenic. The other non-coding variants
were regarded as not being of significance in this context,
either because of their high allele frequencies or location far
from canonical splice sites.
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Genetic and clinical findings in the two patients
with disease-causing variants in PLS3
Patient 1 is a presently 30-year-old Finnish male, who was
found to have a novel hemizygous nonsense variant
(c.766C>T; pArg256*) in exon 8 of PLS3. This variant
is not found in dbSNP, SISu, ExAC, or gnomAD data-
bases and classified as pathogenic according to the
American Collage of Medical Genetics and Genomics
(ACMG) guidelines for interpreting sequence variants
[25]. He has also been sequenced for a core panel of bone
fragility genes (Blueprint Genetics, Helsinki), including
COL1A1 and COL1A2, without pathogenic findings. The
mother of patient 1 was confirmed to be heterozygous for
the variant, while the brother, father, and three maternal
relatives were negative for the variant. Patient 1 has a
history of multiple fractures since early childhood.
Between the ages of 9 and 10 years, he fractured both
femurs in two separate low-energy traumas. At 10 years,
he was diagnosed with multiple vertebral compression
fractures, and at 13 years, he sustained two humeral frac-
tures at two separate occasions. A bone biopsy at the age
of 11 years confirmed the diagnosis of trabecular osteo-
porosis, low bone turnover, and normal mineralization
(Fig. 2 and Supplemental Table 1; Online Resource). He
had considerably low DXA measurements; at 18 years,
the BMD Z-score for the lumbar spine was −4.1 and for
the femoral neck −3.3. He then received a 1-year
treatment with zoledronic acid, and by age 20, a slight
improvement was seen with BMD Z-scores of −3.8 and
−2.8 for lumbar spine and femoral neck (Fig. 3). The
patient also displays some extraskeletal features such as
slightly blue sclerae, slightly yellow teeth and loss of
enamel, generalized joint hyperlaxity, soft skin, minor
aortic valve regurgitation, and asthma. In other respects,
his pubertal development and adult height (175 cm) were
normal. Measurements for calcium, phosphate, and alka-
line phosphate were normal and there was no hypercalci-
uria, but urinary NTX was low (normal creatinine). Taken
together, his biochemical profile was normal except for a
mild vitamin D deficiency (serum 25-OH-vitamin D
35 nmol/L). The mother, heterozygous for the variant,
had osteopenia on DXA scan (total body Z-score −1.4 at
46 years) and had sustained one radius fracture after a fall
at 35 years. The mother also had joint hyperlaxity and
slightly blue sclerae but was otherwise healthy.
Patient 2 whose variant was deemed disease-causing is a
10-year-old Finnish girl with no family history of osteoporo-
sis. She proved to be heterozygous for a novel de novo mis-
sense variant in exon 12 (c.1424A>G; p.N446S) that was
absent in her parents and healthy sister (Supplemental
Fig. 2; Online Resource). The variant was not found in either
dbSNP, SISu, ExAC, or gnomAD databases. The amino acid
in this position is highly conserved over different species, and
the missense variant has a scaled CADD score of 21.5 and is
predicted deleterious by both SIFT and MutationTaster.
Fig. 1 BMD measurements of
the lumbar spine and the proximal
femur in cohort I (left panel,
n = 31) and cohort II (right panel,
n = 64). The bottom two figures
show prevalence of vertebral
compression fractures in the
respective cohorts. Children in
cohort I have in general a lower
BMD Z-score at the lumbar spine
and a higher prevalence of
vertebral compression fractures
(p < 0.005 for both) compared
with cohort II. In cohort I, the two
patients with disease-causing
variants in PLS3 (values
encircled) show a markedly low
BMD compared to other subjects.
(Boys are denoted with a circle
and girls with a cross)
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According to the ACMG guidelines [25], this variant is clas-
sified as likely pathogenic, which means that the variant is
considered to be pathogenic at a level of ≥90% certainty.
However, since the phenotype was significantly more severe
than anticipated for a female with a heterozygous missense
variant in PLS3, we investigated the possibility of other caus-
ative variants. An array-CGH detected no significant gene
dosage imbalances; her other PLS3 allele was also intact. We
also performed whole exome sequencing for patient 2 and her
nuclear family (healthy parents and healthy sister). Since the
parents were completely healthy, the analysis focused on re-
cessively inherited and de novo variants. However, apart from
the de novo variant in PLS3, no other potential disease-
causing variants were found. Importantly, no other damaging
variants were found in any other genes associated with OI.
The genes COL1A1 and COL1A2 had also previously been
Sanger sequenced without pathogenic findings. Moreover,
previously reported female patients heterozygous for patho-
genic variants in PLS3 show variable expressivity [12, 19]
(Supplemental Table 2; Online Resource). Based on these
findings, the heterozygous PLS3 variant was regarded as the
most likely cause for the phenotype.
Patient 2 has a history of multiple long bone and ver-
tebral compression fractures and remarkably low BMD.
By the age of 6 years, she had sustained three low-
energy long bone fractures and one finger fracture and
was then referred to the Metabolic Bone Clinic,
Children’s Hospital, Helsinki for further investigations.
Her BMD Z-scores for the lumbar spine, proximal femur,
and total body were −6.6, −4.5, and −3.5, respectively.
Spinal radiographs showed three asymptomatic vertebral
compression fractures. Extra-skeletal manifestations were
seen in the form of joint hyperlaxity with hyperextension
in elbows and knees, but she did not have blue sclerae.
Secondary causes of osteoporosis were excluded. Serum
calcium, phosphate, alkaline phosphatase, PTH, and vita-
min D were normal. A bone biopsy confirmed the diag-
nosis of trabecular osteoporosis, low bone turnover, and
Table 1 Variations in PLS3 found in the two different cohorts





Coding variants (D) – c.766C>T Nonsense 0.022 –
– c1424A>G Missense 0.022 –
Coding variants (B) rs140121121 c.321T>A Synonymous 0.067 0.0522a
rs2108099 c.1242T>C Synonymous 0.022 0.0409a
rs871774 c.1294T>C Synonymous 0.022 0.0402a
Non-coding variants rs757124 c.-55C>G 5′ UTR 0.38 0.36b
rs201765481 c.501-190del(13 bp) Intronic 0.043 0.059c
rs871773 c.1377+17C>T Intronic 0.022 0.0425a
rs2301951 c.1511+82T>C Intronic 0.022 0.18b
rs190387665 c.1-66C>T Intronic 0.022 0.008b
Cohort II
Coding variants (B) rs140121121 c.321T>A Synonymous 0.035 0.0522a
rs2108099 c.1242T>C Synonymous 0.071 0.0409a
rs871774 c.1294T>C Synonymous 0.059 0.0402a
rs140968059 c.925A>G Missense 0.012 0.003a
Non-coding variants rs757124 c.-55C>G 5′ UTR 0.38 0.36b
rs201765481 c.501-190del(13pb) Intronic 0.082 0.059c
rs871773 c.1377+17C>T Intronic 0.059 0.0425a
rs2301951 c.1511+82T>C Intronic 0.071 0.18b
rs782554235 1635+101G>C Intronic 0.012 0.003b
In total, 12 different allelic variants were found in the two cohorts combined, 7 of them in both cohorts. Two novel variants, both deemed damaging and
causative of disease, were found in two different subjects in cohort I. No variants thought to be damaging were found in cohort II
D damaging, B benign
a SISu database
b dbSNP (144)
c Ninety-six healthy Finnish controls
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normal mineralization (Fig. 2 and Supplemental Table 1;
Online Resource). Treatment with pamidronate was
started at the age of 6 years with a cumulative dose of
9 mg/kg the first year and continued with zoledronic acid
0.025 mg/kg every 6 months thereafter. Follow-up mea-
surements at 17, 29, and 40 months showed a good treat-
ment response and she has not experience new fractures
thereafter (Fig. 4).
Genetic findings in cohort II
In cohort II, Sanger sequencing of the PLS3 gene showed
in total 8 SNVs and 1 small deletion in the 64 patients
with fractures (Table 1). All variants have been previously
described, and most of them corresponded to the findings
in cohort I. One coding variant was unique to cohort II, a
rare missense variant (rs140968059, p.I309V) found in
heterozygous form in one girl. However, the substitution
was predicted benign by both SIFT and MutationTaster,
and both isoleucine and valine are branched-chain amino
acids with very similar chemical structures, making a sub-
stitution between the two less likely to be damaging.
Thus, none of the variants found in the 64 fracture-
prone children were considered causative of their skeletal
fragility.
Discussion
In this study, we have tried to answer two questions: (1)
Are pathogenic variants in PLS3 responsible for a propor-
tion of bone fragility in children? (2) How to better rec-
ognize patients whose bone fragility are caused by path-
ogenic variants in PLS3? We addressed these questions in
the more severely affected children in cohort I and in the
seemingly healthy but fracture-prone children in cohort II.
In cohort I, a non-negligible proportion of the patients
(6.5%; 2 of 31 screened subjects) had variants in PLS3 that
were deemed to be causative of their osteoporosis. In the
case of patient 1, the 30-year-old Finnish male was hemizy-
gous for a novel nonsense variant located in the mid-part of
the gene. Such a variant, based on what is known, leads to a
complete loss of function of the mature protein and the
patient will effectively be left without any functioning copy
of PLS3 [26, 27]. Both the inheritance pattern and the phe-
notype of previously described patients with premature stop
codons in PLS3 support this conclusion [12, 15]. PLS3 is
also recognized as a gene with extremely low tolerance to
protein truncating variants (probability of loss of function
intolerance (pLI) = 0.99) [28].
In patient 2, the 10-year-old Finnish female, we detect-
ed a novel de novo heterozygous missense variant. Other
Fig. 2 Iliac crest bone biopsies from both patients with disease-causing
variants in PLS3. The upper panels (a and b) show biopsy from patient 1,
and the lower panels (c and d) biopsy from patient 2. Both subjects
display trabecular osteoporosis, low bone turnover, and normal
mineralization. Panels a and c show low trabecular bone volume and
low trabecular thickness. Panels b and d show low osteoid surface and
reduced numbers of osteoblasts and osteoclasts in line with low bone
turnover
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potential genetic causes were excluded by array-CGH and
whole exome sequencing. PLS3 is also considered sensi-
tive to missense variants (Z-score 2.51) ranking in the top
15% of genes most sensitive to missense variants [28].
Early-onset symptomatic osteoporosis has previously
been described in adult females with heterozygous patho-
genic variants in PLS3 [12, 19] but perhaps not to the
extent seen in this 10-year-old girl. Our findings therefore
extend the phenotypic spectrum of PLS3 osteoporosis to
include also girls with severe primary osteoporosis.
Previously reported patients with severe osteoporosis
due to pathogenic variants in PLS3 have almost all been
male, and in general males tend to be more severely af-
fected. In 2015, Laine et al. reported on a large Finnish
family with osteoporosis due to a pathogenic splice vari-
ant in PLS3. In this large family, hemizygous males had
more severe osteoporosis, but all heterozygous females
had low BMD and one affected female had a phenotype
more in resemblance with her male relatives, with recur-
rent peripheral fractures and multiple vertebral compres-
sion fractures [19]. Van Djik et al. also reported a variable
clinical phenotype in females with heterozygous
pathogenic variants in PLS3 [12] (Supplemental Table 2;
Online Resource). In our study, variable expressivity can
also be seen in females with heterozygous pathogenic
variants; the mother of patient 1 had a mild phenotype
while patient 2 had severe osteoporosis. The cause of this
variable expressivity is not known. Some variants could
perhaps have a dominant negative effect on the other al-
lele, but since this variable expressivity can be seen also
within families where all affected share the same patho-
genic variant, other factors are likely to contribute.
Skewed X-inactivation could explain why female patients
with identical genotypes can display different phenotypic
severity, but modifying variants in regulatory elements
could also exert an effect on the phenotype. Moreover,
lifestyle factors may influence the phenotypic presentation
even in monogenic forms of osteoporosis.
Pathogenic variants in PLS3 seem to have a substantial
impact on BMD and involve compression fractures of the
vertebrae. In cohort I, among the 31 included patients, the
Fig. 4 Radiographs of patient 2 with PLS3 osteoporosis. At 6 years (a),
spinal osteoporosis can be seen together with several compressed
vertebrae. At this time, bisphosphonate treatment was started. (b) Two
years later, an improvement in the radiographic appearance can be seen.
(c) Graph of lumbar spine BMD after initiation of bisphosphonate
treatment (shaded areas denote Z-scores ±2.0)
Fig. 3 Radiographs and BMD of patient 1 with PLS3 osteoporosis.
Spinal radiograph (a) at the age of 12 years shows a kyphosis and a
significant spinal osteoporosis with compressed vertebrae. Radiograph
(b) at 21 years, after a 1-year zoledronic acid treatment, shows an im-
provement of kyphosis and the shape of vertebrae, but his BMD remained
very low. Long bone radiographs (c) at the age of 21 years show gener-
alized osteopenia and very thin cortices in the lower leg. (d) Lumbar spine
BMD from childhood to adulthood (shaded areas denote Z-scores ±2.0)
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two described patients stood out with the lowest and third
lowest BMD Z-score at the lumbar spine and the lowest and
second lowest BMD at the femoral neck. Both patients also
had a history of multiple vertebral compression fractures as an
indication of significant spinal osteoporosis, which seems to
be a hallmark for PLS3 osteoporosis. They also had a history
of multiple major low-energy long bone fractures at an early
age. Bone histomorphometry confirmed in both patients tra-
becular osteoporosis with low bone turnover and normal min-
eralization. The low bone turnover in PLS3 osteoporosis
stands in contrast to the high bone turnover seen in type I
collagen-related osteogenesis imperfecta [29]. These findings
are in line with previous reports on patients with osteoporosis
due to pathogenic variants in PLS3 [12, 15, 19].
Treatment with bisphosphonates has been evaluated for
only a handful of patients with PLS3 osteoporosis, but all
these reports suggest that treatment is at least initially benefi-
cial for increasing BMD [12, 15]. In patient 1, the year-long
treatment with zoledronic acid, which started as late as at
18 years, increased his BMD only slightly and 1 year after
discontinuation his BMD was still very low. In patient 2,
bisphosphonate treatment, which started at a much younger
age, has significantly improved BMD and prevented further
fractures, but long-term treatment results remain yet to be
seen.
In cohort II, consisting of seemingly healthy but fracture-
prone children, no disease-causing PLS3 sequence variants
were found. We also looked for enrichment of both rare and
common SNVs that, at least in theory, could be modifiers of
protein function and perhaps help to explain the wide range in
the number of childhood fractures seen in the general popula-
tion. However, we did not find any enriched PLS3 SNVs in
cohort II and conclude that PLS3 variations do not explain
increased bone fragility in this large cohort of children.
Based on our findings, and the previously reported cases, it
seems that clinically relevant pathogenic variants in PLS3 re-
sult not only in increased long bone fractures but are always
associated with significantly reduced BMD and vertebral
fractures.
We recognize some limitations in our study. Our cohorts
were relatively small and this limits our ability to make strong
conclusions in the overall pediatric population and may have
prevented us from finding significant associations.
Furthermore, we only searched for variants that were thought
to directly affect protein structure (exonic or splice variants),
which means that other possibly important variants in introns
or regulatory regions could not be detected. However, because
of our fairly stringent inclusion criteria, we believe that our
results are representative of patients assessed in pediatric bone
clinics for suspected primary osteoporosis. This is also, to our
knowledge, the first study that systematically screened for
PLS3 variants in a single-hospital based cohort of children
with bone fragility, and the finding of two novel pathogenic
or likely pathogenic variants inPLS3 supports the relevance of
our research approach. We did not perform functional studies
to evaluate the mechanisms through which the variants lead to
clinical manifestations and it thus remains unknown whether
the missense variant leads to protein instability or otherwise
infers with PLS3 function. Such studies were beyond the
scope of this study but once more data emerges about the
physiological role of PLS3 in skeletal homeostasis, functional
evaluation of mutated PLS3may provide important insights to
the pathogenesis of PLS3 osteoporosis.
Conclusions
This study expands the spectrum of disease-causing PLS3
variants and the associated phenotypes; it gives further sup-
port to the importance of spinal osteoporosis as a consequence
of pathogenic variants in PLS3 and indicates that also females
with heterozygous pathogenic variants in PLS3 can develop
childhood-onset primary osteoporosis. Based on our findings,
PLS3 screening should be considered in children—both boys
and girls—with multiple peripheral and spinal fractures and
low BMD. Molecular diagnosis is important for appropriate
patient management and genetic counseling even if specific
treatment for PLS3 osteoporosis is not yet available. In con-
trast, children who show an increased propensity to fracture
but do not fulfill the criteria of osteoporosis (i.e., have BMD
within the normal range) are less likely to have disease-
causing variants in PLS3, and our study does not provide
support that screening for PLS3 variants in these children is
meaningful.
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